MENLO PARK, Calif., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM) today provided an update on its development program for ADVM-043 (formerly “ANN-001”), a novel gene therapy for Alpha-1 Antitrypsin (A1AT) Deficiency, a rare genetic...

Paul Cleveland Named Executive Chairman of the Board Amber Salzman, Ph.D. Named CEO MENLO PARK, Calif., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a gene therapy company committed to discovering and developing novel medicines for...

MENLO PARK, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, announced...

Data Show Promising Efficacy and Safety Profile of ADVM-022 and ADVM-032 MENLO PARK, Calif., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM) a gene therapy company committed to discovering and developing novel medicines for patients...

MENLO PARK, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, today...

Collaboration Brings Together Vector and Ophthalmology Expertise of Adverum with Genome Editing Capabilities of Editas MENLO PARK, Calif. and CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM) and Editas Medicine, Inc....

MENLO PARK, Calif., July 07, 2016 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM) today announced the Company will continue to move forward with preclinical development of its anti-VEGF wAMD gene therapy candidates after analyzing promising...

MENLO PARK, Calif., June 13, 2016 /PRNewswire/ -- Adverum Biotechnologies, Inc. (NASDAQ: ADVM) a gene therapy company committed to discovering and developing novel medicines for patients living with rare diseases or diseases of the eye who currently have limited...

—New Trading Symbol (NASDAQ:ADVM) Effective May 12, 2016— -New Management Team and Additional Board Members in Place- MENLO PARK, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL) today announced the closing of the previously...

MENLO PARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL) today announced that its stockholders, at its annual meeting held today, approved the issuance of shares of the Company’s common stock to the shareholders of Annapurna...